Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
You may also be interested in...
Lilly said it will seek accelerated approval in the US based on Phase II data for its amyloid-clearing antibody, potentially narrowing Biogen/Eisai’s newly approved therapy Aduhelm’s time on the market as the only disease-modifying Alzheimer’s drug.
Biogen/Eisai’s aducanumab, as the first disease-modifying therapy and setting a precedent for accelerated approval, lifted the entire Alzheimer’s field.
New data show that early-stage Alzheimer’s trials increasingly are sponsored by government and nonprofit organizations, while another review illustrates diversification of the clinical pipeline.